RxDoctor Payments Data

Arthur Ronan, DO

Family Medicine · Okemos, MINPI 1346283074

Payments from drug & device makers

$5,957in general payments, 2019–2025

Across 331 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$818
  • Novo Nordisk$421
  • Lilly USA, LLC$295
  • Pfizer$263
  • Merz North America, Inc.$202
  • plus $3K from 45 others

What the payments were for

  • Food & beverage$5,957100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,957 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$16,513
Medicare patients
46
Services billed
282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xeljanz XrTofacitinib Citrate13$74,104
OzempicSemaglutide44$50,657
OxycontinOxycodone Hcl25$40,875
EliquisApixaban41$29,569
MyrbetriqMirabegron34$18,248
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$16,346
XareltoRivaroxaban15$14,845
Xtampza ErOxycodone Myristate13$14,483
MounjaroTirzepatide14$14,362
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$12,884
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,906
Breo ElliptaFluticasone/Vilanterol11$4,168
Oxycodone Hcl138$2,969
Levemir FlexpenInsulin Detemir13$2,636
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen127$1,948

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$421$50,65744 claims
PfizerEliquis$263$29,56941 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$61$26,42136 claims
Astellas Pharma US IncMyrbetriq$41$18,24834 claims
Johnson & JohnsonXarelto$109$14,84515 claims
Collegium Pharmaceutical, Inc.Xtampza Er$22$14,48313 claims
Lilly USA, LLCMounjaro$295$14,36214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Okemos

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →